CrestPoint Capital Management’s AbbVie ABBV Stock Holding History

CrestPoint Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$890K	Sell	9,200 -100	-1%	-$9.43K	0.49%	74
2017 Q3	$826K	Buy	9,300 +1,300	+16%	+$99K	0.37%	94
2017 Q2	$580K	Buy	8,000 +1,000	+14%	+$67.2K	0.27%	127
2017 Q1	$456K	Buy	7,000 +1,100	+19%	+$69.2K	0.22%	144
2016 Q4	$369K	Sell	5,900 -600	-9%	-$36.6K	0.18%	162
2016 Q3	$410K	Sell	6,500 -100	-2%	-$6.47K	0.21%	151
2016 Q2	$409K	Sell	6,600 -700	-10%	-$42.7K	0.22%	147
2016 Q1	$417K	Buy	7,300 +1,100	+18%	+$61.3K	0.23%	141
2015 Q4	$367K	Buy	+6,200	New	+$357K	0.21%	135

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

CrestPoint Capital Management's ABBV Position: Q4 2017 in Review

CrestPoint Capital Management reduced its AbbVie (ABBV) stake by 1.1% in Q4 2017, selling an estimated $9.43K and leaving 9,200 shares worth $890K. The position accounts for 0.49% of the portfolio, ranked #74.

CrestPoint Capital Management first reported a position in ABBV in Q4 2015 and has held it in 9 quarters since. 2,001 funds tracked by Wall St. Rank hold ABBV as of Q4 2017.

CrestPoint Capital Management held 9,200 shares of AbbVie worth $890K as of Q4 2017.
CrestPoint Capital Management sold 100 AbbVie shares in Q4 2017, an estimated $9.43K.
AbbVie made up 0.49% of CrestPoint Capital Management's portfolio in Q4 2017, its #74 holding.
CrestPoint Capital Management first reported a position in AbbVie in Q4 2015 and has held it in 9 quarters since.
2,001 funds tracked by Wall St. Rank held AbbVie as of Q4 2017.

Based on CrestPoint Capital Management's 13F filing for Q4 2017, filed 17 Jan 2018.